抗体薬物複合体（ADC）のグローバル市場動向...市場調査レポートについてご紹介

1. Analyst View
2. Research Methodology
3. Antibody Drug Conjugate (ADC) – An Introduction
4. ADC Market Outlook to 2020
4.1 ADCETRIS
4.1.1 Market Potential
4.1.2 Market Size and Forecasts to 2020
4.2 Kadcyla
4.2.1 Market Potential
4.2.2 Market Size and Forecasts to 2020
5. ADC Pipeline Analysis
5.1 By Phase
5.2 By Indication
5.3 By Drug
6. Drivers and Challenges
6.1 Drivers
6.1.1 Advances in Linking Technologies Re-Instills Hope in ADC
6.1.2 Efforts towards Patent Protection to Drive ADC Market
6.2 Challenges
6.2.1 Production Hurdles and Cost
6.2.2 Inadequacy of Experienced Manufacturers
6.2.3 Regulatory Challenges
7. Current Status of Potential ADCs in Pipeline
7.1 Glembatumumab Vedotin Therapeutics /CDX-011 – Celldex
7.2 Coltuximab Ravtansine/SAR3419 – Immunogen Inc.
7.3 Indatuximab Ravtansine/BT-062 – Biotest
7.4 Anti-PSMA ADC Therapeutic – Progenics Pharmaceuticals
7.5 Polatuzumab Vedotin/RG7596 – Roche Genentech
7.6 Pinatuzumab Vedotin/RG7593 – Roche Genentech
7.7 Lifastuzumab Vedotin/RG7599 – Roche Genentech
7.8 Anti-guanylyl Cyclase C/Anti-GCC ADC – Takeda Millennium
7.9 Inotuzumab Ozogamicin (CMC-544) – Pfizer
8. Trends and Developments
8.1 ADC at the Forefront to Treat Hematological Malignancies
8.2 ADCs Providing Advantages to Breast Cancer Patients
9. Strategic Collaborations in the ADC Industry
10. Competitive Assessment
10.1 Seattle Genetics
10.2 Roche
10.3 Immunogen, Inc.
10.4 Bayer Healthcare
10.5 Novartis
10.6 Immunomedics
10.7 Agensys, Inc

List of Figures

Figure 3-1: ADC – Mechanism of Action
Figure 4-1: Global – ADC Market (Billion US$), 2014-2020
Figure 4-2: Global – ADCETRIS Market (Million US$), 2011-2013
Figure 4-3: Global – ADCETRIS Market (Billion US$), 2014-2020
Figure 4-4: Global – Kadcyla Market (Billion US$), 2014-2020
Figure 5-1: Pipeline ADCs by Clinical Phase (2014)
Figure 5-2: Pipeline ADCs by Indication (2014)
Figure 5-3: Pipeline ADCs by Drug (2014)

List of Tables

Table 4-1: Potential Patients for ADCETRIS (2012)
Table 4-2: Ongoing Trials for ADCETRIS
Table 4-3: Potential Patients for Kadcyla (2012)
Table 4-4: Ongoing Trials for Kadcyla
Table 7-1: ADCs in Pipeline
Table 9-1: Strategic Collaborations in ADC Industry
Table 10-1: Top Companies by ADCs in Pipeline (2014)
Table 10-2: Seattle Genetics – ADCs in Pipeline
Table 10-3: Seattle Genetics – ADCs Collaborator Pipeline
Table 10-4: Seattle Genetics – Strengths and Weaknesses
Table 10-5: Roche – ADC Collaborator Pipeline
Table 10-6: Roche – Strengths and Weaknesses
Table 10-7: Immunogen, Inc. – ADCs in Pipeline
Table 10-8: Immunogen, Inc. – ADC Collaborator Pipeline
Table 10-9: Immunogen, Inc. – Strengths and Weaknesses
Table 10-10: Bayer Healthcare – ADCs in Pipeline
Table 10-11: Bayer Healthcare – Strengths and Weaknesses
Table 10-12: Novartis Pharmaceuticals – ADCs in Pipeline
Table 10-13: Novartis Pharmaceuticals – Strengths and Weaknesses
Table 10-14: Immunomedics – ADCs in Pipeline
Table 10-15: Immunomedics – Strengths and Weaknesses
Table 10-16: Agensys, Inc. – ADC Collaborator Pipeline
Table 10-17: Agensys, Inc. – Strengths and Weaknesses